Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Rybnicek

Gastroenterology Hendersonville, NC Medical Doctor

NPI 1134480197 CMS profile 794235

1032 Fleming Street, Hendersonville, NC 28791

Open in the dashboard

General payments

$7,289

414 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Rybnicek of Hendersonville, NC is reported in the CMS Open Payments database as having received $7,289 across 414 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,285 68
2024 General $1,427 72
2023 General $1,287 73
2022 General $1,099 65
2021 General $878 61
2020 General $606 42
2019 General $708 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Rybnicek
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Rybnicek were reported at $1,285. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Rybnicek Gastroenterology median Middle half National median
2019 $708 $417 $126–$1,100 $163
2020 $606 $224 $74–$624 $114
2021 $878 $352 $106–$1,054 $132
2022 $1,099 $448 $129–$1,270 $149
2023 $1,287 $533 $150–$1,390 $160
2024 $1,427 $605 $160–$1,606 $164
2025 $1,285 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,042 140 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $827 45 payments
  3. Janssen Biotech, Inc. $567 35 payments
  4. Gilead Sciences, Inc. $530 25 payments
  5. Ironwood Pharmaceuticals, Inc $483 25 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $379 22 payments
  7. PENTAX of America, Inc. $334 8 payments
  8. Pfizer Inc. $259 16 payments
  9. Intercept Pharmaceuticals, Inc. $185 9 payments
  10. Phathom Pharmaceuticals, Inc. $175 11 payments
  11. Other $1,507 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,238 412 payments
  2. Education $51 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $640 41 payments
  2. ENTYVIO $513 27 payments
  3. MAVYRET $490 41 payments
  4. Linzess $483 25 payments
  5. HUMIRA $418 29 payments
  6. STELARA $368 26 payments
  7. XIFAXAN $362 21 payments
  8. SKYRIZI Immunology $301 21 payments
  9. CREON $249 15 payments
  10. SKYRIZI Immunology $249 17 payments
  11. Other $3,875 205 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

475

Median for Internal Medicine: 777

Drug cost

$34,099

Median for Internal Medicine: $73,373

Branded share of claims

39.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 25 $22,094
Dexlansoprazole Dr Dexlansoprazole Brand 12 $5,253
Omeprazole Generic 209 $2,565
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 121 $2,166
Dicyclomine Hcl Generic 17 $558
Pantoprazole Sodium Generic 28 $505
Famotidine Generic 33 $399
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 18 $286
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 12 $274

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$351,610

Of which drugs: $167,839

Medicare patients

744

Average age 74

Services billed

12,506

426 women, 318 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 49%
Depression 28%
Diabetes 25%
Ischemic heart disease 24%
Atrial fibrillation 22%
Chronic kidney disease 22%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 13 6,304 $109,724

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Linzess
  • Ironwood Pharmaceuticals, Inc $126
$126 25 —
DUPIXENT
  • GENZYME CORPORATION $74
  • Regeneron Healthcare Solutions, Inc. $41
$115 — —
RINVOQ
  • AbbVie, Inc. $100
$100 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $87
$87 — —
SKYRIZI
  • AbbVie, Inc. $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

414 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record